Cimzia prefilled syringe delivers certolizumab pegol in a ready-to-use format for adults with Crohn’s disease, rheumatoid arthritis and other immune conditions. Anyone holding UCB stock (NASDAQ: UCBJY ...
(HealthDay)—Cimzia (certolizumab pegol) injection has been approved to treat adults with nonradiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, the U.S. Food and Drug ...
The Food and Drug Administration (FDA) has approved Cimzia to treat certain inflammatory conditions in adults, including rheumatoid arthritis. It’s also FDA approved for polyarticular juvenile ...
A self-injection pen prefilled with Brussels-based UCB’s Cimzia (certolizumab pegol) has been made available this week in the U.K. after a positive opinion from the EMA. UCB developed the AutoClicks ...
The Cimzia prefilled pen from UCB aims to make biologic therapy for conditions like rheumatoid arthritis and axial spondyloarthritis feel a little less clinical and a bit more manageable at home. What ...
* EMA has recommended the Cimzia dose dispenser cartridge for use with the re-usable ava electronic injection device in all approved indications Source text: bit.ly/2qcXlVg Further company coverage: ...
Cimzia and Humira are both FDA-approved biologics that treat inflammatory conditions by preventing the immune system from attacking healthy cells. While both medications can cause injection site ...
Cimzia (certolizumab) is a prescription drug used to treat some types of arthritis and other conditions. Cimzia can cause side effects that range from mild to serious. Examples include infection and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results